Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

21.73 -0.56 (-2.51%)
Streaming Delayed Price Updated: 2:40 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 180,379
Open 22.50
Bid (Size) 21.70 (2)
Ask (Size) 21.76 (1)
Prev. Close 22.29
Today's Range 21.61 - 22.50
52wk Range 11.16 - 27.98
Shares Outstanding 44,454,792
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) – An Undervalued Stock Worth Considering
PACIRA BIOSCIENCES (NASDAQ:PCRX) offers an undervalued opportunity with strong profitability, manageable debt, and steady growth, making it a candidate for value investors. 
Via Chartmill
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pacira BioSciences
Via GlobeNewswire

Performance

YTD
+18.5%
+18.5%
1 Month
-10.9%
-10.9%
3 Month
-11.8%
-11.8%
6 Month
-1.5%
-1.5%
1 Year
+3.5%
+3.5%

More News

Read More
Lifshitz Law PLLC Announces Investigations of Sun Communities, Inc. (NYSE: SUI), Pacira Biosciences, Inc. (NASDAQ: PCRX), ModivCare, Inc. (NASDAQ: MODV), and Integral Ad Science Holding Corp. (NASDAQ: IAS)
Via ACCESS Newswire
Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025
From Pacira BioSciences
Via GlobeNewswire
Earnings Scheduled For May 8, 2025
Via Benzinga
Preview: Pacira BioSciences's Earnings
Via Benzinga
PACIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Pacira BioSciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) – An Undervalued Stock with Strong Fundamentals
Via Chartmill
Lifshitz Law PLLC Announces Investigations of DMC Global Inc. (NASDAQ: BOOM), Sun Communities, Inc. (NYSE: SUI), Pacira Biosciences, Inc. (NASDAQ: PCRX), and ModivCare, Inc. (NASDAQ: MODV)
Via ACCESS Newswire
Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pacira BioSciences
Via GlobeNewswire
Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX); and Treace Medical Concepts, Inc. (NASDAQ: TMCI)
From Grabar Law Office
Via GlobeNewswire
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) – An Undervalued Stock with Solid Fundamentals
Via Chartmill
Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
From Pacira BioSciences
Via GlobeNewswire
Where Pacira BioSciences Stands With Analysts
Via Benzinga
Pacira BioSciences Reports First Quarter 2025 Financial Results
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis
From Pacira BioSciences
Via GlobeNewswire
Don't overlook PACIRA BIOSCIENCES INC (NASDAQ:PCRX)—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis
From Pacira BioSciences
Via GlobeNewswire
PACIRA BIOSCIENCES INC (NASDAQ:PCRX): An Affordable Growth Stock Worth Watching
Via Chartmill
Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025
From Pacira BioSciences
Via GlobeNewswire
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is an undervalued gem with solid fundamentals.
Via Chartmill
Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee
From Pacira BioSciences
Via GlobeNewswire

Frequently Asked Questions

Is Pacira BioSciences, Inc. - Common Stock publicly traded?
Yes, Pacira BioSciences, Inc. - Common Stock is publicly traded.
What exchange does Pacira BioSciences, Inc. - Common Stock trade on?
Pacira BioSciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Pacira BioSciences, Inc. - Common Stock?
The ticker symbol for Pacira BioSciences, Inc. - Common Stock is PCRX on the Nasdaq Stock Market
What is the current price of Pacira BioSciences, Inc. - Common Stock?
The current price of Pacira BioSciences, Inc. - Common Stock is 21.73
When was Pacira BioSciences, Inc. - Common Stock last traded?
The last trade of Pacira BioSciences, Inc. - Common Stock was at 07/18/25 02:40 PM ET
What is the market capitalization of Pacira BioSciences, Inc. - Common Stock?
The market capitalization of Pacira BioSciences, Inc. - Common Stock is 966.00M
How many shares of Pacira BioSciences, Inc. - Common Stock are outstanding?
Pacira BioSciences, Inc. - Common Stock has 966M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS